JANE STREET GROUP, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.

Quarter-by-quarter ownership
JANE STREET GROUP, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$5,679,242
+4.9%
125,121
+29.7%
0.00%0.0%
Q2 2023$5,415,882
-10.8%
96,471
-28.1%
0.00%0.0%
Q1 2023$6,070,318
+111.5%
134,210
+90.1%
0.00%
+100.0%
Q4 2022$2,869,484
+568.9%
70,590
+974.4%
0.00%
Q3 2022$429,000
-93.7%
6,570
-94.1%
0.00%
-100.0%
Q2 2022$6,770,000
-87.4%
111,415
-87.0%
0.00%
-83.3%
Q1 2022$53,641,000
-28.3%
854,579
-13.4%
0.02%
-28.0%
Q4 2021$74,823,000
-16.5%
987,378
+23.3%
0.02%
-21.9%
Q3 2021$89,621,000
-57.2%
800,696
-38.0%
0.03%
-61.0%
Q2 2021$209,172,000
+35.6%
1,292,061
+2.0%
0.08%
+7.9%
Q1 2021$154,298,000
+14.0%
1,266,286
+43.2%
0.08%
+11.8%
Q4 2020$135,388,000
+424.1%
884,249
+186.3%
0.07%
+353.3%
Q3 2020$25,832,000
+16.2%
308,843
+2.1%
0.02%
-6.2%
Q2 2020$22,231,000
+951.6%
302,494
+506.8%
0.02%
+700.0%
Q1 2020$2,114,000
+13.5%
49,850
+63.1%
0.00%
-50.0%
Q4 2019$1,862,000
+231.9%
30,565
+156.7%
0.00%
+300.0%
Q2 2019$561,000
+150.4%
11,907
+90.2%
0.00%
Q1 2019$224,000
-80.0%
6,261
-84.1%
0.00%
-100.0%
Q4 2018$1,122,000
-71.1%
39,274
-55.2%
0.00%
-75.0%
Q3 2018$3,886,000
+194.4%
87,626
+290.3%
0.01%
+166.7%
Q2 2018$1,320,000
+49.0%
22,452
+15.9%
0.00%
+50.0%
Q1 2018$886,00019,3730.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2020
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders